The FDA has approved an expanded indication for Medtronic’s OmniaSecure defibrillation lead, making it the first defibrillation lead cleared for placement in the left bundle branch area for conduction system pacing. The lead can now support left bundle branch optimized cardiac resynchronization therapy, combining conduction system pacing with left-ventricular pacing to improve patient outcomes.
At just 4.7 French (1.66 mm), the OmniaSecure is the smallest diameter defibrillation lead on the market. It connects to implantable cardioverter-defibrillators or cardiac resynchronization therapy defibrillators to treat life-threatening arrhythmias and bradyarrhythmias. The device builds on technology from the SelectSecure Model 3830 pacing lead, the first lead approved for conduction system pacing in 2022.
The approval was supported by the global LEADR LBBAP trial, which demonstrated 100% defibrillation success at implant and a 2.1% complication rate at three months when the lead was placed in the left bundle branch area. The lumenless construction enables catheter delivery and precise placement, representing a significant advancement in cardiac rhythm management.